Clinical trials: Dementia, Alzheimer Type
Coronary Artery Disease, Diabetes Mellitus, Type 2
PIPAF Platelets in the Pathogenesis of Ageing Associated Frailty
This is a prospective observational study aimed at testing the existence of an association between frailty, inflammatory status, and degree of platelet activation and reactivity in elderly subjects with type 2 diabetes or…
- Conditions
- Coronary Artery Disease, Diabetes Mellitus, Type 2, Alzheimer Disease
- Trial name
- PIPAF (NCT05798637)
- Testing
- Standard of care
- Where
- 2 sites in Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Perugia
Agitation Associated With Alzheimer's Disease, Alzheimer's Type
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.
- Conditions
- Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02192554
- Where
- 84 sites in United States, Bulgaria and 10 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease, Dementia, Mild
Paper-Based and Smartphone-Based Memory Supports
Alzheimer's disease and related dementias lead to marked declines in daily functioning, independence, and quality of life. One of the earliest cognitive changes in these conditions is impairment in prospective memory, or the…
- Conditions
- Alzheimer Disease, Dementia, Mild, Mild Cognitive Impairment
- Trial name
- NCT06444841
- Testing
- Digital - Google Calendar, Paper-based - Memory Support System
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Baylor University
Alzheimer's Disease
Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease
The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.
- Trial name
- NCT00130429
- Testing
- PYM50028
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Phytopharm
Dementia Alzheimer's Type
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Primary Objective: To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC) on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to Alzheimer's disease…
- Trial name
- NCT02667496
- Testing
- Sargramostim GZ402664, Florbetapir F18
- Where
- United States
- Sponsor
- Sanofi
Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease
Rifaximin SSD in Dementia Trial
Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.
- Trial name
- RIDE (NCT06718686)
- Testing
- Rifaximin SSD 40 mg IR tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jasmohan Bajaj
Alzheimer Disease, Cognitive Dysfunction
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type is a pivotal, single blind, parallel design, multi-site study intends…
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia
- Trial name
- NCT03721705
- Testing
- Renew NCP-5
- Where
- 12 sites in United States, Ireland and 1 more
- Volunteers
- 190 people
- Sponsor
- Renew Research, LLC
Alzheimer Disease, Mild Cognitive Impairment
tDCS and Cognitive Training for Mild Cognitive Impairment and Alzheimer's Dementia
There are currently no disease-modifying treatments for cognitive and behavioral symptoms associated with early clinical Alzheimer's disease (AD), and only minimally effective symptomatic treatments are available.
- Trial name
- NCT04507815
- Testing
- Active Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Mild Cognitive Impairment, Alzheimers Disease
Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type
The purpose of the study is to compare the concentrations of Vitamin B1 (thiamine), Vitamin B6 (pyridoxal-5-phosphate), folate, Vitamin B12 (cobalamin), Vitamin C (ascorbic acid), Vitamin A (retinol), Vitamin E (alfa-tocopherol)…
- Trial name
- ALZ-vit (NCT01479855)
- Where
- Norway
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Mild Cognitive Impairment (MCI), Subjective Memory Complaint
Validation of a Digital Intervention to Rehabilitate Cognitive Resources
The goal of this clinical trial is to learn if the use of a digital cognitive rehabilitation system named RICORDO, that is flexible and capable of adapting the rehabilitation pathway according to the needs and capacity of the…
- Conditions
- Mild Cognitive Impairment (MCI), Subjective Memory Complaint, Dementia Alzheimer Type
- Trial name
- MI-RICORDO (NCT07064226)
- Testing
- RICORDO, Treatment as Usual (TAU)
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Alzheimer Dementia
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
This study is a multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group clinical trial.
- Trial name
- NCT07066826
- Testing
- Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Alzheimer's Disease
Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
The purpose of this study is to evaluate the efficacy and safety of galantamine in patients who failed to benefit from donepezil (patients switching from donepezil).
- Trial name
- NCT01478633
- Testing
- Galantamine
- Where
- 11 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Janssen Pharmaceutical K.K.
Alzheimer's Disease
Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00411580
- Testing
- CAD106
- Where
- 3 sites in Sweden
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Dementia, Alzheimer's Disease
Association of Cognition With Functional Mobility in People With Alzheimer's Disease
This study aimed to investigate relationship between cognitive function and functional mobility in Alzheimer's disease.
- Conditions
- Alzheimer Dementia, Alzheimer's Disease, Dementia, Alzheimer Type
- Trial name
- NCT05113732
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Istanbul University - Cerrahpasa
Dementia, Mixed, Dementia, Vascular
Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
The STAREE-Mind imaging sub-study will examine the effect of statin treatment over a 4-year period, compared with placebo, on markers of brain health.
- Conditions
- Dementia, Mixed, Dementia, Vascular, Dementia of Alzheimer Type, Cognitive Decline
- Trial name
- STAREE-Mind (NCT05586750)
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- 2 sites in Australia
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- Monash University
Parkinson Disease, Diabetes Mellitus, Type 1
Biological Sample Collection for Research and Biobanking
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to study different conditions and diseases by using cells from the body (such as skin or blood cells).
- Conditions
- Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS
- Trial name
- NCT04270604
- Testing
- Biological sample collection
- Where
- United States
- Volunteers
- 1,279 people, healthy volunteers welcome
- Sponsor
- New York Stem Cell Foundation Research Institute
Stroke, Stroke (CVA) or TIA
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors.
- Conditions
- Stroke, Stroke (CVA) or TIA, Dementia, Vascular, Cerebrovascular Disorders
- Trial name
- IC3 (NCT05885295)
- Testing
- MRI brain, Blood tests, cognitive assessments
- Where
- United Kingdom
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Depression, Stress, Psychological
Rural Dementia Caregiver Project
Rural caregivers face challenges of geographic isolation and lower health care access and quality. Many rural dementia caregivers experience serious health consequences due to caregiving responsibilities that can limit their…
- Conditions
- Depression, Stress, Psychological, Self Efficacy, Loneliness
- Trial name
- NCT04428112
- Testing
- Building Better Caregivers Workshop, Attention Control
- Where
- United States
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pre Diabetes
Assessment of the Impact of a Personalised Nutrition Intervention in Impaired Glucose Regulation
This study will determine if DNA-based dietary guidelines can improve glucose regulation in pre-diabetic individuals significantly more than standard dietary guidelines following 6 weeks of the intervention.
- Trial name
- ASPIRE-DNA (NCT03702465)
- Testing
- DNA-based dietary intervention, DNA-based dietary intervention using an app, Control arm
- Where
- United Kingdom
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Imperial College London